Site Start-Up in Clinical Trials: From Feasibility to First Subject Enrolled
Site start-up is the process of preparing and activating a research site so it can begin enrolling subjects. It runs from the first feasibility questions through regulatory document collection, IRB submission, contract negotiation, and the site initiation visit. Done well, it means the difference between an on-time study launch and months of delay. Done poorly, it slows the whole program and adds cost.
The Clarity Clinical Solutions training module on site start-up walks through every step of that journey. The goal is simple to state and hard to execute: move a site from identification to fully operational as fast as possible, without cutting regulatory corners. Every delay in this phase hits the study timeline and the budget directly.
Feasibility comes first
Start-up begins with feasibility. Sponsors and contract research organizations evaluate candidate sites on investigator qualifications and experience, patient population, facilities and equipment, staff capacity, and prior regulatory compliance history. The feasibility questionnaire gathers this information in a structured way and helps decide whether a site fits the study.
Thorough feasibility prevents a costly mistake: selecting a site that cannot recruit, or cannot perform to the protocol. The effort spent here pays for itself later.
Document collection: the regulatory binder takes shape
Once a site is selected, document collection starts. The essential documents include the signed FDA Form 1572, current curricula vitae for the investigator and all sub-investigators, medical licenses, and proof of good clinical practice training. Financial disclosure forms, laboratory certifications and normal ranges, and the investigator's brochure acknowledgement are also required. Together these form the investigator regulatory binder, the official record of site compliance.
Missing or incorrect documents are the most common cause of start-up delays. The FDA spells out what belongs in the file: Form 1572 is the Statement of Investigator, the signed agreement between the investigator and the FDA that establishes the investigator's responsibilities under an investigational new drug application (FDA FAQ on Form 1572). Sponsors also need to complete and submit the form properly, and the FDA publishes step-by-step instructions for both Forms 1571 and 1572 (FDA: How to Complete Form FDA 1571 and Form FDA 1572).
IRB approval gates every research activity
Before any research activity can begin, an Institutional Review Board or independent ethics committee must approve the protocol. The submission package includes the protocol, informed consent form, investigator's brochure, recruitment materials, and other subject-facing documents. Sites can use a local IRB or a central IRB for multicenter trials.
Review timelines vary widely, from about two weeks to several months, depending on whether the review is expedited or full board and how heavy the IRB's workload is. The informed consent form is a critical deliverable in this phase. It has to be written in language a layperson can understand and must include the elements required by 21 CFR Part 50, the FDA regulation on protection of human subjects: purpose, procedures, risks, benefits, alternatives, confidentiality, and the voluntary nature of participation (21 CFR Part 50 — Protection of Human Subjects). The IRB must approve the consent form before anyone uses it. Version control matters throughout.
Budget and contract: the longest step
While documents move through review, the site and sponsor negotiate the clinical trial agreement and study budget. The budget covers per-patient costs, start-up fees, administrative overhead, and pass-through expenses. The CTA defines the legal terms: publication rights, confidentiality, termination clauses, indemnification.
Negotiation is frequently the single longest step in start-up, often running 60 to 90 days. Early alignment on financial terms can accelerate the whole timeline.
The site initiation visit
The site initiation visit, or SIV, is the final gate. The sponsor's clinical research associate visits the site to train the team on the protocol, case report forms, investigational product handling, adverse event reporting, and regulatory compliance. Everyone who will work on the study attends. The SIV also includes a review of regulatory documents to confirm everything is in order.
Only after the SIV is completed and documented does the site officially activate and begin screening subjects. The ICH good clinical practice guidelines describe this qualification and initiation process as part of the sponsor's responsibility to ensure sites are prepared to conduct trials properly (ICH E6(R2) Good Clinical Practice).
Where the delays hide
The most frequent causes of start-up delay are slow contract and budget negotiation, incomplete or incorrect regulatory documents, IRB backlogs, and poor communication between site and sponsor. Sites without dedicated regulatory staff struggle to assemble document packages quickly. Sponsors cause their share too, with late delivery of the investigator's brochure or study drug.
Sponsors and CROs fight these bottlenecks with a few proven tactics. Pre-qualifying sites through a master feasibility database cuts selection time. Standardized regulatory document templates and central IRBs speed submissions. Running contract negotiations in parallel with document collection, rather than one after the other, can save weeks. Electronic regulatory binders let sponsors review documents in real time. Clear milestones and regular communication keep everyone accountable.
Technology is changing the phase. Electronic regulatory management systems let sites upload documents for immediate sponsor review. CTMS platforms track milestones and send automated reminders for pending items. E-consent solutions support remote consent review. Central IRB portals streamline submissions. These tools cut manual data entry, reduce errors, and give sponsors visibility into start-up status across every site.
Readiness check before activation
Before declaring a site activated, run a final readiness check. Confirm all regulatory documents are complete, signed, and current. Make sure IRB approval is in hand and the approved consent form is ready. Verify the investigational product has arrived and is stored correctly. Confirm all staff completed required training. Check that equipment is calibrated and supplies are on hand. Document the verification in the site file.
Activating a site that is not fully ready risks subject safety and data integrity. It is far cheaper to delay activation by a week than to correct a compliance problem discovered after enrollment starts.
The bottom line
Site start-up is a multi-step process that demands coordination among site, sponsor, CRO, and IRB. The phases are consistent: feasibility, regulatory document collection, IRB submission, contract negotiation, and the site initiation visit. Delays usually trace back to document errors, budget discussions, and communication gaps. Parallel processing, electronic systems, and central IRBs compress the timeline. And a thorough readiness check before activation prevents costly corrections later. Efficient start-up is one of the most direct levers a sponsor has on study timelines and development costs.
This article is based on the Clarity Clinical Solutions video "Understanding Site Start-Up in Clinical Trials." Watch it here: Understanding Site Start-Up in Clinical Trials
References
- Clarity Clinical Solutions — "Understanding Site Start-Up in Clinical Trials" (framework for this article). https://www.youtube.com/watch?v=a1pobAVRXhU
- FDA — Frequently Asked Questions: Statement of Investigator (Form FDA 1572); explains the investigator's regulatory commitments. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/frequently-asked-questions-statement-investigator-form-fda-1572
- FDA — How to Complete Form FDA 1571 and Form FDA 1572; official instructions for IND forms. https://www.fda.gov/news-events/expanded-access/how-complete-form-fda-1571-and-form-fda-1572
- eCFR — 21 CFR Part 50, Protection of Human Subjects; informed consent requirements. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50
- ICH — E6(R2) Good Clinical Practice guideline; sponsor responsibilities for site qualification and initiation. https://www.ich.org/page/e6r2